Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2820 Target Snapshot

Coagulation factor XI · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
3,720Compounds
266Assays
1Approved Drugs
5,364.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Coagulation factor XI shows approved-linked disease relevance led by hereditary angioedema. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P03951. Start with hereditary angioedema, then reuse UniProt P03951 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with hereditary angioedema, then reuse UniProt P03951 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
hereditary angioedema

Coagulation factor XI shows approved-linked disease relevance led by hereditary angioedema. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with hereditary angioedema because it currently carries approved-linked support. Linked drugs include HUMAN C1-ESTERASE INHIBITOR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Coagulation factor XI as ChEMBL target CHEMBL2820, mapped to UniProt P03951. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Coagulation factor XI
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2820
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P03951
Coagulation factor XI
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Coagulation factor XI is the right protein anchor across sources, using UniProt P03951 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why hereditary angioedema is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameCoagulation factor XI
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP03951
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCoagulation factor XI
UniProt AccessionP03951
Component TypeProtein
Sequence Length625 aa

Coagulation factor XI

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Coagulation factor XI, mapped to UniProt P03951. Sequence length is 625 aa.

Mapped IDP03951
Review nameCoagulation factor XI
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Coagulation factor XI shows approved-linked disease relevance led by hereditary angioedema. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
hereditary angioedema
1 linked drug · 1 direct · 1 efficacy
Linked drugHUMAN C1-ESTERASE INHIBITOR
Late clinical Phase III
atrial fibrillation
2 linked drugs · 2 direct · 2 efficacy
Linked drugABELACIMAB
Linked drugMILVEXIAN
Late clinical Phase III
acute coronary syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugMILVEXIAN
Late clinical Phase III
angioedema
1 linked drug · 1 direct · 1 efficacy
Linked drugHUMAN C1-ESTERASE INHIBITOR
Late clinical Phase III
venous thromboembolism
1 linked drug · 1 direct · 1 efficacy
Linked drugABELACIMAB
Clinical signal Phase II
COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugHUMAN C1-ESTERASE INHIBITOR
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with hereditary angioedema because it currently carries approved-linked support. Linked drugs include HUMAN C1-ESTERASE INHIBITOR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasehereditary angioedema
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
1
Phase III
1
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC503,244.0
KI2,099.0
EC5012.0
KD9.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4096251 10.7 Ki 0.02 Preclinical
CHEMBL4060950 10.52 Ki 0.03 Preclinical
CHEMBL4107149 10.52 Ki 0.03 Preclinical
CHEMBL3580759 10.4 Ki 0.04 Preclinical
CHEMBL4110926 10.4 Ki 0.04 Preclinical
CHEMBL6039093 10.4 Ki 0.04 Preclinical
CHEMBL4112773 10.3 Ki 0.05 Preclinical
CHEMBL4114881 10.3 Ki 0.05 Preclinical
CHEMBL4097522 10.22 Ki 0.06 Preclinical
CHEMBL4109568 10.22 Ki 0.06 Preclinical
Distribution

pChEMBL Value Distribution

186
5.0
200
5.5
413
6.0
425
6.5
715
7.0
656
7.5
742
8.0
528
8.5
331
9.0
144
9.5
pChEMBL
Assay Landscape

Assay Landscape

266
Total Assays
2,964
Tested Compounds
2
Assay Types
Binding — 265 assays, 2,964 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 257 2,891 7.6
cell-based format 4 0 —
assay format 2 72 6.6
cell-free format 2 1 9.5
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine